Drug cocktail boosts ovarian cancer survival time

June 2, 2012

A drug cocktail that combines chemotherapy with Avastin was shown to double the amount of time patients lived without progression of ovarian cancer, according to research released Saturday.

Also known as bevacizumab and marketed as Avastin by the Swiss Roche, the drug could help women who have a resistant form of the cancer, researchers said.

"For the first time in platinum resistant ovarian cancer, we have been able to significantly improve progression free survival with a combination therapy," said lead study author Eric Pujade-Lauraine, a professor at Universite de Paris Descartes.

"These results are very significant because the addition of bevacizumab offers a new treatment option for the 20 percent of women who have primary platinum resistant disease, as well as those whose disease later becomes platinum-resistant."

The international, randomized phase III clinical trial included 361 patients with ovarian cancer. Some received bevacizumab in addition to standard chemotherapies; others received chemo treatments alone.

The median time of progression free survival was 6.7 months in the combination therapy group, compared to 3.4 months in chemotherapy alone group.

Previous research has shown that can be effective as a first and second line treatment against ovarian cancer, and future studies may shed more light on when how long to administer it.

The latest research was presented at the annual conference of the in Chicago.

Some 230,000 women are diagnosed each year worldwide with . About 70 percent of patients die within five years of diagnosis.

Explore further: New drug combination slows tumor growth for recurrent ovarian cancer

Related Stories

New drug combination slows tumor growth for recurrent ovarian cancer

June 6, 2011
Bevacizumab (Avastin) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III "OCEANS" trial were presented today by ...

Targeted therapy extends progression-free survival of patients with advanced ovarian cancer

December 28, 2011
Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer. A new phase 3 clinical trial conducted by the Gynecologic ...

Experimental drug inhibits cell signaling pathway and slows ovarian cancer growth

April 15, 2011
An experimental drug that blocks two points of a crucial cancer cell signaling pathway inhibits the growth of ovarian cancer cells and significantly increases survival in an ovarian cancer mouse model, a study at UCLA's Jonsson ...

Recommended for you

One in five young colon cancer patients have genetic link

December 13, 2017
As doctors grapple with increasing rates of colorectal cancers in young people, new research from the University of Michigan may offer some insight into how the disease developed and how to prevent further cancers. Researchers ...

New strategy for unleashing cancer-fighting power of p53 gene

December 13, 2017
Tumor protein p53 is one of the most critical determinants of the fate of cancer cells, as it can determine whether a cell lives or dies in response to stress. In a new study published today in the journal Nature Communications, ...

Researchers develop test that can diagnose two cancer types

December 12, 2017
A blood test using infrared spectroscopy can be used to diagnose two types of cancer, lymphoma and melanoma, according to a study led by Georgia State University.

Cancer-causing mutation suppresses immune system around tumours

December 12, 2017
Mutations in 'Ras' genes, which drive 25% of human cancers by causing tumour cells to grow, multiply and spread, can also protect cancer cells from the immune system, finds a new study from the Francis Crick Institute and ...

Atoh1, a potential Achilles' heel of Sonic Hedgehog medulloblastoma

December 12, 2017
Medulloblastoma is the most common type of solid brain tumor in children. Current treatments offer limited success and may leave patients with severe neurological side effects, including psychiatric disorders, growth retardation ...

MRI scans predict patients' ability to fight the spread of cancer

December 12, 2017
A simple, non-invasive procedure that can indicate how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy has been developed by researchers in Liverpool.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.